Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Primary and secondary metastatic dissemination: multiple routes to cancer-related death.

Molecular cancer·2025
Same author

Leptomeningeal metastasis from solid tumours: EANO-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2023
Same author

Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.

Journal of neuro-oncology·2023
Same author

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022
Same author

Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.

BMC cancer·2022
Same author

How we identify and treat neuromuscular toxicity induced by immune checkpoint inhibitors.

ESMO open·2021
Same journal

[When brain abscesses run in the family…].

Der Nervenarzt·2026
Same journal

[Digital health applications and adherence in depression: a qualitative study from the perspective of healthcare providers].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

[Rare genetic diseases with frequent mental symptoms].

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
Same journal

Der Nervenarzt·2026
See all related articles

Related Experiment Video

Updated: Apr 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K

[Personalized therapy for gliomas].

W Wick1, P Hau

  • 1Abteilung Neuroonkologie, Neurologische Klinik und Nationales Zentrum für Tumorerkrankungen, Universitätsklinikum Heidelberg, INF 400, 69120, Heidelberg, Deutschland, wolfgang.wick@dkfz.de.

Der Nervenarzt
|May 30, 2015
PubMed
Summary
This summary is machine-generated.

Personalized malignant glioma treatments are improving with molecular factors and age integration. Biomarkers like MGMT promoter methylation and 1p/19q codel enhance diagnosis, prognostication, and targeted immunotherapies for better patient outcomes.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Related Experiment Videos

Last Updated: Apr 11, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.2K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.6K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Area of Science:

  • Neuro-oncology
  • Molecular Biology
  • Genetics

Context:

  • Malignant gliomas lack sufficiently individualized therapies despite integrating molecular factors and age.
  • Advances in basic science are being translated into clinical applications for glioma treatment.

Purpose:

  • To review current advancements in glioma therapy personalization.
  • To highlight the role of molecular factors, biomarkers, and imaging in improving diagnosis, prognostication, and treatment response assessment.

Summary:

  • Current glioma therapies are evolving to incorporate molecular factors and age, moving towards personalized treatment.
  • Key molecular biomarkers such as O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation and 1p/19q codeletion are integrated for improved diagnosis and prognostication.
  • Targeted therapies and immunotherapies are being developed using biomarkers like epidermal growth factor receptor (EGFRvIII) and IDH-1 mutations.
  • Functional imaging parameters and imaging biomarkers are crucial for monitoring treatment response and guiding therapy.

Impact:

  • Improved classification of prognostic groups and enhanced survival times for specific glioma subgroups.
  • Maintained functional status and quality of life in patients undergoing optimized therapies.
  • Anticipation of more precise, molecularly-driven brain tumor classification and therapy guidance with early response assessment.